Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan-Feb;19(1):174-7.
doi: 10.4103/2230-8210.146879.

Insulin-derived amyloidosis

Yashdeep Gupta  1 , Gaurav Singla  2 , Rajiv Singla  3
Affiliations

Insulin-derived amyloidosis

Yashdeep Gupta et al. Indian J Endocrinol Metab. 2015 Jan-Feb.

Abstract

Amyloidosis is the term for diseases caused by the extracellular deposition of insoluble polymeric protein fibrils in tissues and organs. Insulin-derived amyloidosis is a rare, yet significant complication of insulin therapy. Insulin-derived amyloidosis at injection site can cause poor glycemic control and increased insulin dose requirements because of the impairment in insulin absorption, which reverse on change of injection site and/or excision of the mass. This entity should be considered and assessed by histopathology and immunohistochemistry, in patients with firm/hard local site reactions, which do not regress after cessation of insulin injection at the affected site.

Search strategy: PubMed was searched with terms "insulin amyloidosis". Full text of articles available in English was reviewed. Relevant cross references were also reviewed. Last search was made on October 15, 2014.

Keywords: Diabetes; insulin; insulin injection; insulin resistance; localized amyloidosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Seldin DC, Skinner M. Amyloidosis. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. USA: McGraw-Hill Companies, Inc; 2012. pp. 945–50.
    1. Shikama Y, Kitazawa J, Yagihashi N, Uehara O, Murata Y, Yajima N, et al. Localized amyloidosis at the site of repeated insulin injection in a diabetic patient. Intern Med. 2010;49:397–401. - PubMed
    1. Störkel S, Schneider HM, Müntefering H, Kashiwagi S. Iatrogenic, insulin-dependent, local amyloidosis. Lab Invest. 1983;48:108–11. - PubMed
    1. D’souza A, Theis JD, Vrana JA, Dogan A. Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration. Amyloid. 2014;21:71–5. - PMC - PubMed
    1. Nagase T, Iwaya K, Iwaki Y, Kotake F, Uchida R, Oh-i T, et al. Insulin-derived amyloidosis and poor glycemic control: A case series. Am J Med. 2014;127:450–4. - PubMed